title: Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice.
abstract: OBJECTIVE
  In this article, we studied the effect of acetyl-11-keto-beta-boswellic acid (AKbetaBA), a natural inhibitor of the proinflammatory transcription factor NF-kappaB on the development of atherosclerotic lesions in apolipoprotein E-deficient (apoE-/-) mice.
  
  
  RESULTS
  Atherosclerotic lesions were induced by weekly LPS injection in apoE-/- mice. LPS alone increased atherosclerotic lesion size by approximately 100%, and treatment with AKbetaBA significantly reduced it by approximately 50%. Moreover, the activity of NF-kappaB was also reduced in the atherosclerotic plaques of LPS-injected apoE-/- mice treated with AKbetaBA. As a consequence, AKbetaBA treatment led to a significant downregulation of several NF-kappaB-dependent genes such as MCP-1, MCP-3, IL-1alpha, MIP-2, VEGF, and TF. By contrast, AKbetaBA did not affect the plasma concentrations of triglycerides, total cholesterol, antioxidized LDL antibodies, and various subsets of lymphocyte-derived cytokines. Moreover, AKbetaBA potently inhibited the IkappaB kinase (IKK) activity immunoprecipitated from LPS-stimulated mouse macrophages and mononuclear cells leading to decreased phosphorylation of IkappaB alpha and inhibition of p65/NF-kappaB activation. Comparable AKbetaBA-mediated inhibition was also observed in LPS-stimulated human macrophages.
  
  
  CONCLUSIONS
  The inhibition of NF-kappaB activity by plant resins from species of the Boswellia family might represent an alternative for classical medicine treatments for chronic inflammatory diseases such as atherosclerosis.
authors.affiliation: INSERM UR545, Institut Pasteur de Lille, 1 rue du Professeur Calmette, 59019 Lille, France.
authors.forename: Clarisse
authors.initials: C
authors.lastname: Cuaz-Pérolin
authors.forename: Ludivine
authors.initials: L
authors.lastname: Billiet
authors.forename: Eric
authors.initials: E
authors.lastname: Baugé
authors.forename: Corinne
authors.initials: C
authors.lastname: Copin
authors.forename: Daniel
authors.initials: D
authors.lastname: Scott-Algara
authors.forename: Felicitas
authors.initials: F
authors.lastname: Genze
authors.forename: Berhold
authors.initials: B
authors.lastname: Büchele
authors.forename: Tatiana
authors.initials: T
authors.lastname: Syrovets
authors.forename: Thomas
authors.initials: T
authors.lastname: Simmet
authors.forename: Mustapha
authors.initials: M
authors.lastname: Rouis
mesh_terms: D000818:Animals; D001057:Apolipoproteins E / Q000235:genetics*; D050197:Atherosclerosis / Q000188:drug therapy* / Q000235:genetics; D029743:Boswellia; D002478:Cells, Cultured; D004195:Disease Models, Animal; D007249:Inflammation / Q000188:drug therapy; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D018345:Mice, Knockout; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000187:drug effects*; D010936:Plant Extracts / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*
chemical_list: D001057:Apolipoproteins E; D008070:Lipopolysaccharides; D016328:NF-kappa B; D010936:Plant Extracts; D014315:Triterpenes; C094432:acetyl-11-ketoboswellic acid